keyword
MENU ▼
Read by QxMD icon Read
search

PRRT

keyword
https://www.readbyqxmd.com/read/27904799/a-clinical-guide-to-the-assessment-and-treatment-of-breathing-pattern-disorders-in-the-physically-active-part-2-a-case-series
#1
Jena Hansen-Honeycutt, Erin B Chapman, Alan Nasypany, Russell T Baker, Jim May
INTRODUCTION: Breathing pattern disorders (BPDs) are characterized by persistent, suboptimal breathing strategies that may result in additional musculoskeletal pain and/or dysfunction. The purpose of this case series was to examine the effects of Primal Reflex Release Technique (PRRT) and breathing exercise interventions in physically active individuals that presented with a primary complaint of musculoskeletal pain, a BPD, and startle reflexes. SUBJECTS: The assessment techniques described in Part 1 of this series were used to identify three student athletes (aged 16-22) who presented with musculoskeletal pain of the low back, mid back, and knee, BPDs, and startle reflexes...
December 2016: International Journal of Sports Physical Therapy
https://www.readbyqxmd.com/read/27885372/treatment-planning-in-prrt-based-on-simulated-pet-data-and-a-pbpk-model-determination-of-accuracy-using-a-pet-noise-model
#2
Deni Hardiansyah, Wei Guo, Ali Asgar Attarwala, Peter Kletting, Felix M Mottaghy, Gerhard Glatting
AIM: To investigate the accuracy of treatment planning in peptide-receptor radionuclide therapy (PRRT) based on simulated PET data (using a PET noise model) and a physiologically based pharmacokinetic (PBPK) model. METHODS: The parameters of a PBPK model were fitted to the biokinetic data of 15 patients. True mathematical phantoms of patients (MPPs) were the PBPK model with the fitted parameters. PET measurements after bolus injection of 150 MBq (68)Ga-DOTATATE were simulated for the true MPPs...
November 25, 2016: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/27873240/improved-safety-and-efficacy-of-213-bi-dotatate-targeted-alpha-therapy-of-somatostatin-receptor-expressing-neuroendocrine-tumors-in-mice-pre-treated-with-l-lysine
#3
Ho Sze Chan, Mark W Konijnenberg, Tamara Daniels, Monique Nysus, Mehran Makvandi, Erik de Blois, Wouter A Breeman, Robert W Atcher, Marion de Jong, Jeffrey P Norenberg
BACKGROUND: Targeted alpha therapy (TAT) offers advantages over current β-emitting conjugates for peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors. PRRT with (177)Lu-DOTATATE or (90)Y-DOTATOC has shown dose-limiting nephrotoxicity due to radiopeptide retention in the proximal tubules. Pharmacological protection can reduce renal uptake of radiopeptides, e.g., positively charged amino acids, to saturate in the proximal tubules, thereby enabling higher radioactivity to be safely administered...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/27863564/designing-and-developing-pet-based-precision-model-in-thyroid-carcinoma-the-potential-avenues-for-a-personalized-clinical-care
#4
REVIEW
Sandip Basu, Rahul Vithalrao Parghane
This communication enumerates the current uses and potential areas where PET could be clinically utilized for developing "precision medicine" type model in thyroid carcinoma. (1) In routine clinics, PET imaging (with fluorodeoxyglucose [FDG]) is utilized to investigate patients of differentiated thyroid carcinoma (DTC) with high thyroglobulin and negative iodine scintigraphy (TENIS) and in medullary carcinoma thyroid (MCT) when the tumor markers (eg, calcitonin and carcino embryonic antigen [CEA]) are raised postoperatively (PET with FDG, (68)Ga-DOTA-NOC/TATE, FDOPA)...
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27853048/does-combination-of-cold-and-hot-somatostatin-analogs-prolong-survival-of-patients-with-neuroendocrine-neoplasms
#5
Anna Sowa-Staszczak, Agnieszka Stefanska, Pawel Chrapczynski, Malgorzata Trofimiuk-Müldner, Miroslaw Szura, Alicja Hubalewska-Dydejczyk
A number of detected neuroendocrine neoplasms (NENs) has been on the increase due to our awareness of the NENs risk and the development of different imaging techniques. Therapy of NENs involves surgery, chemotherapy, "cold" somatostatin analogs (SSA), peptide receptor radionuclide therapy (PRRT) and kinase inhibitors in pancreatic NENs. The aim of this study is to assess the efficacy of SSA in combination with "hot" somatostatin analogs, and the survival rate of our patients with advanced NENs. Seventy nine patients with metastatic NEN and positive somatostatin receptor scintigraphy (SRS) were enrolled in the study...
November 17, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/27789751/teaching-case-nuclear-imaging-in-metastatic-paraganglioma
#6
Rohit Kedia, Neil Hansen, Whitney Goldner
Paragangliomas associated with succinate dehydrogenase subunit D (SDHD) mutations can occasionally result in distant metastasis. Diagnosis can be difficult, and nuclear imaging is used to further evaluate. Not all tumors are alike and may have different nuclear avidity. We present a case of metastatic SDHD paraganglioma with a negative Iodine-123-Meta-Iodobenzylguanidine ((123)I-MIBG) and a positive 111 Indium-labelled octreotide scintigraphy ((111)In-OCT). This presents an opportunity for a novel therapeutic approach for metastatic paraganglioma using targeted peptide receptor radionuclide therapy (PRRT)...
October 27, 2016: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/27759712/peptide-receptor-radionuclide-therapy-outcomes-in-a-north-american-cohort-with-metastatic-well-differentiated-neuroendocrine-tumors
#7
Nancy Sharma, Boris G Naraev, Eric G Engelman, M Bridget Zimmerman, David L Bushnell, Thomas M OʼDorisio, M Sue OʼDorisio, Yusuf Menda, Jan Müller-Brand, James R Howe, Thorvardur R Halfdanarson
OBJECTIVES: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). METHODS: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. RESULTS: The median age at diagnosis was 51 years, and 64% were men...
October 18, 2016: Pancreas
https://www.readbyqxmd.com/read/27749410/successful-repeated-peptide-receptor-radionuclide-therapies-in-renal-neuroendocrine-tumor-with-osseous-metastasis
#8
Anna Yordanova, Karin Mayer, Markus Essler, Hojjat Ahmadzadehfar
Renal neuroendocrine tumor (NET) is an extremely rarely occurring disease. The sporadic reports in the literature are mostly case reports, or less commonly small studies. In cases of metastatic disease from renal NET, there are no established therapies. We are reporting our experience with a patient with extensive osseous infiltration of a renal NET, who was successfully treated with peptide receptor radionuclide therapy (PRRT) using Lu-DOTATATE. In a period of 10 years, the patient underwent in total 12 cycles of PRRT with a cumulative dose of 81 GBq...
October 5, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27743210/predictive-value-of-asphericity-in-pretherapeutic-111-in-dtpa-octreotide-spect-ct-for-response-to-peptide-receptor-radionuclide-therapy-with-177-lu-dotatate
#9
Christoph Wetz, I Apostolova, I G Steffen, F Hofheinz, C Furth, D Kupitz, J Ruf, M Venerito, S Klose, Holger Amthauer
PURPOSE: The purpose of this study was to assess the value of the spatial heterogeneity of somatostatin receptor (SSR) volume, quantified as asphericity (ASP), and to predict response to peptide receptor radionuclide therapy (PRRT) in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). PROCEDURES: From June 2011 to May 2013, patients suffering from GEP-NEN who underwent pretherapeutic [(111)In-DTPA(0)]octreotide scintigraphy (Octreoscan®) prior to [(177)Lu-DOTA(0)-Tyr(3)]octreotate ([(177)Lu]DOTATATE)-PRRT were enrolled in this retrospective evaluation...
October 14, 2016: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/27713064/aggressive-pituitary-adenomas-the-dark-side-of-the-moon
#10
Stefano M Priola, Felice Esposito, Salvatore Cannavò, Alfredo Conti, Rosaria V Abbritti, Valeria Barresi, Sergio Baldari, Francesco Ferraù, Antonino Germanò, Francesco Tomasello, Filippo F Angileri
BACKGROUND: Although pituitary adenomas are considered benign lesions, a small group may exhibit a clinically aggressive behavior, sometimes independently from the classic markers of aggressiveness, including the Ki67 labeling index and/or p53 expression. METHODS: We selected 7 subjects harboring a pituitary tumor with clinical features of aggressiveness. Patients underwent a full preoperative and postoperative endocrinological and neuroradiological work-up. Two were non-functioning, two PRL-secreting, two ACTH-secreting, and one a GH-secreting adenoma...
October 3, 2016: World Neurosurgery
https://www.readbyqxmd.com/read/27705948/survival-prediction-in-patients-undergoing-radionuclide-therapy-based-on-intratumoral-somatostatin-receptor-heterogeneity
#11
Rudolf A Werner, Constantin Lapa, Harun Ilhan, Takahiro Higuchi, Andreas K Buck, Sebastian Lehner, Peter Bartenstein, Frank Bengel, Imke Schatka, Dirk O Muegge, László Papp, Norbert Zsótér, Tobias Große-Ophoff, Markus Essler, Ralph A Bundschuh
The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the prognostic value of tumor heterogeneity as assessed by somatostatin receptor (SSTR)-PET/CT. 141 patients with SSTR-expressing tumors were analyzed obtaining SSTR-PET/CT before PRRT (1-6 cycles, 177Lu somatostatin analog)...
October 2, 2016: Oncotarget
https://www.readbyqxmd.com/read/27704193/long-term-follow-up-and-role-of-fdg-pet-in-advanced-pancreatic-neuroendocrine-patients-treated-with-177-lu-d-otatate
#12
Maddalena Sansovini, Stefano Severi, Annarita Ianniello, Silvia Nicolini, Lorenzo Fantini, Emilio Mezzenga, Fabio Ferroni, Emanuela Scarpi, Manuela Monti, Alberto Bongiovanni, Sara Cingarlini, Chiara Maria Grana, Lisa Bodei, Giovanni Paganelli
PURPOSE: Lu-DOTATATE (Lu-PRRT) is a valid therapeutic option in differentiated pancreatic neuroendocrine tumors (P-NETs). FDG PET seems to be an important prognostic factor in P-NETs. We evaluated the efficacy of Lu-PRRT and the role of FDG PET in 60 patients with advanced P-NETs. METHODS: From March 2008 to June 2011, 60 consecutive patients with P-NETs were enrolled in the study. Follow-up lasted until March 2016. Eligible patients were treated with two different total cumulative activities (18...
October 4, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27678267/high-clinical-and-morphologic-response-using-90-y-dota-octreotate-sequenced-with-177-lu-dota-octreotate-induction-peptide-receptor-chemoradionuclide-therapy-prcrt-for-bulky-neuroendocrine-tumours
#13
Grace Kong, Jason Callahan, Michael S Hofman, David A Pattison, Tim Akhurst, Michael Michael, Peter Eu, Rodney J Hicks
PURPOSE: Bulky disease is an adverse prognostic factor for (177)Lu-DOTA-octreotate ((177)Lu-DOTATATE) peptide receptor radionuclide therapy (PRRT). (90)Y-DOTA-octreotate ((90)Y-DOTATATE) has theoretical advantages in this setting but may less effectively treat co-existent smaller deposits and have higher toxicity than (177)Lu-DOTATATE. The aim of this study was to assess the efficacy and safety of using these agents sequentially. METHODS: We reviewed patients (pts) with at least one lesion of a transaxial diameter >4 cm who completed 1-2 cycles of (90)Y-DOTATATE followed by 2-3 cycles of (177)Lu-DOTATATE, with treatment empirically adapted to disease size and burden in individual patients...
September 27, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27659006/influence-of-voxel-s-factors-on-three-dimensional-internal-dosimetry-calculations
#14
Salvatore Berenato, Ernesto Amato, Alexander Fischer, Sergio Baldari
Internal dosimetry is a fundamental instrument for the personalization of nuclear medicine therapies, to maximize the therapeutic effect while minimizing the radiation burden to other organs. Three-dimensional (3D) dosimetry can quantify the impact of heterogeneous radiopharmaceutical distributions in organs, lesions and tissues. We analysed the influence of radionuclide voxel S factors in 3D dosimetry of (111)In, (177)Lu and (90)Y, the most used radionuclides in Peptide Receptor Radionuclide Therapy (PRRT)...
September 19, 2016: Physica Medica: PM
https://www.readbyqxmd.com/read/27636009/heterogeneity-of-grade-3-gastroenteropancreatic-neuroendocrine-carcinomas-new-insights-and-treatment-implications
#15
Nicola Fazio, Massimo Milione
Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are currently classified as grade (G) 1, G2 and G3, in accordance with the 2010 WHO classification. G1 and G2 are named neuroendocrine tumors (NETs) whereas G3 neuroendocrine carcinomas (NECs). While advanced G1 and G2 are usually treated with several different therapies, including somatostatin analogs, chemotherapy, interferon, molecular targeted agents, peptide receptor radionuclide therapy (PRRT) and liver-directed treatments, advanced G3 NECs are usually treated with a platinum-etoposide chemotherapy, trusting their clinical homogeneity is similar to that of small cell lung cancer...
August 28, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27635672/treatment-of-symptomatic-neuroendocrine-tumor-syndromes-recent-advances-and-controversies
#16
Tetsuhide Ito, Lingaku Lee, Robert T Jensen
INTRODUCTION: Neuroendocrine tumors(NETs), once thought rare, are increasing in frequency in most countries and receiving increasing-attention. NETs present two-treatment problems. A proportion is aggressive and a proportion has a functional, hormone-excess-state(F-NET) each of which, must be treated. Recently, there have been many advances, well-covered in reviews/consensus papers on imaging-NETs; new, novel anti-tumor treatments and understanding their pathogenesis. However, little attention has been paid to advances in the treatment of the hormone-excess-state...
September 16, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27634982/177lu-dotatate-prrt-as-promising-new-treatment-approach-in-recurrent-skull-base-phosphaturic-mesenchymal-tumor-causing-paraneoplastic-oncogenic-osteomalacia-a-potential-therapeutic-application-of-prrt-beyond-net
#17
Sandip Basu, Preeti Fargose
The potential of peptide receptor radionuclide therapy (PRRT) is described in recurrent inoperable phosphaturic mesenchymal tumor involving left basi-occiput causing tumor-induced osteomalacia (TIO), for which the patient had undergone two times surgery previously. Following one cycle of PRRT, there was good symptomatic improvement, modest reduction of uptake on both (68)Ga-DOTATATE PET/CT and FDG-PET/CT suggesting favourable response and hence was considered for second cycle. Being somatostatin receptor avid, this rare group of tumors when inoperable or recurrent may be potentially targeted with PRRT...
September 15, 2016: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/27624551/prrt2-from-paroxysmal-disorders-to-regulation-of-synaptic-function
#18
Flavia Valtorta, Fabio Benfenati, Federico Zara, Jacopo Meldolesi
In the past few years, proline-rich transmembrane protein (PRRT)2 has been identified as the causative gene for several paroxysmal neurological disorders. Recently, an important role of PRRT2 in synapse development and function has emerged. Knock down of the protein strongly impairs the formation of synaptic contacts and neurotransmitter release. At the nerve terminal, PRRT2 endows synaptic vesicle exocytosis with Ca(2+) sensitivity by interacting with proteins of the fusion complex and with the Ca(2+) sensors synaptotagmins (Syts)...
October 2016: Trends in Neurosciences
https://www.readbyqxmd.com/read/27613553/resection-of-the-primary-tumor-followed-by-peptide-receptor-radionuclide-therapy-as-upfront-strategy-for-the-treatment-of-g1-g2-pancreatic-neuroendocrine-tumors-with-unresectable-liver-metastases
#19
Emilio Bertani, Nicola Fazio, Davide Radice, Claudio Zardini, Chiara Grana, Lisa Bodei, Luigi Funicelli, Carlo Ferrari, Francesca Spada, Stefano Partelli, Massimo Falconi
BACKGROUND: A low burden of disease represents an independent favorable prognostic factor of response to peptide receptor radionuclide therapy (PRRT) in patients affected by gastro-entero-pancreatic neuroendocrine tumors. However, it is not clear whether this is due to a lower diffusion of the disease or thanks to debulking surgery. METHODS: From 1996 to 2013 those patients diagnosed with G1-G2 pancreatic neuroendocrine tumor (PNET) and synchronous liver metastases who were not deemed eligible for liver radical surgery but were eligible to receive upfront PRRT were prospectively included in the study...
September 9, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27612032/comparison-of-renal-uptake-of-68ga-dotanoc-pet-ct-and-estimated-glomerular-filtration-rate-before-and-after-peptide-receptor-radionuclide-therapy-in-patients-with-metastatic-neuroendocrine-tumours
#20
Chalermrat Kaewput, Sobhan Vinjamuri
BACKGROUND: Ga-DOTA-conjugated peptide PET/CT is used widely for diagnosis and treatment planning in patients with neuroendocrine tumours. As nephrotoxicity is a major limiting factor during peptide receptor radionuclide therapy (PRRT), it is important to evaluate renal function before, during and after treatment. The aim of our study is to compare renal uptake of Ga-DOTANOC and estimated glomerular filtration rate (eGFR) before and after PRRT and to identify any surrogate indicators of renal toxicity...
September 8, 2016: Nuclear Medicine Communications
keyword
keyword
83339
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"